- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- Study from NCPA sheds new light on med synchronization programs
- Reports: ESI may start 'price war' over new hepatitis C drugs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
EAST BRUNSWICK — Drug maker Savient Pharmaceuticals has begun shipping its new gout treatment to specialty distributors, the company said Tuesday.
Savient announced the shipment of Krystexxa (pegloticase), saying it would become available by prescription starting Wednesday.
The drug, designed for administration by IV, received approval on Sept. 14 from the Food and Drug Administration for treating chronic gout.